Torys LLP acted for Entos Pharmaceuticals. On January 6, 2022, Eli Lilly and Company (NYSE:LLY) acquired exclusive rights to Entos’ Fusogenix nucleic acid delivery technology to research,…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Sonia Carcano
…
This content is for Standard 1 Year members only. LoginJoin Now